Hamilton General Hospital

Summary

Hamilton General Hospital is a medical facility located in HAMILTON, Ontario. This center is recognized for care of Stroke, Atrial Fibrillation, Central Venous Access Device Thrombosis, Heart Attack, Blood Clot and other specialties. Hamilton General Hospital is involved with conducting 194 clinical trials across 295 conditions. There are 30 research doctors associated with this hospital, such as Principal Investigator, Jeff S Healey, MD, Maureen Meade, and Richard Whitlock, MD.

Top PIs

Clinical Trials running at Hamilton General Hospital

Atrial Fibrillation

Heart Failure

Stroke

Coronary Artery Disease

Cardiovascular Disease

Cardiotoxicity

Cancer

Bleeding

Peripheral Artery Disease

Postoperative Pain

Blood Thinners

for Atrial Fibrillation

This trial is testing whether taking blood-thinning pills can prevent strokes and other heart issues in patients who have temporary irregular heartbeats and are at risk of stroke after surgery. These pills are a recent breakthrough in preventing strokes.

Recruiting

3 awards

Phase 4

4 criteria

Amiodarone

for Post-Operative Atrial Fibrillation

The START-POAF pilot study is a prospective, open-label two-arm, randomized controlled trial with blinded assessment of outcomes (PROBE). This pilot study will assess Atrial Fibrillation (AF) recurrence and burden in patients with new-onset AF following cardiac surgery.

Recruiting

2 awards

Phase 3

3 criteria

Virtual Visits

for Atrial Fibrillation

The purpose of the PAUSE-Virtual Study is to show that by changing pre-surgery visits with patients taking a blood thinner (direct oral anticoagulant (apixaban, dabigatran, edoxaban, rivaroxaban or warfarin) when the participant requires elective surgery, using a standard, in-person proven approach, to a virtual visit, either telephone or video conference, is as safe. Patients who are receiving a blood thinner for the medical condition known as atrial fibrillation (AF) and require an elective surgery/procedure, is common. These patients have to stop taking their blood thinner for a certain time before the procedure to reduce serious complications of stroke or bleeding. For doctors who help manage these patients before a procedure, appointments have been traditionally done in-person. Patients receive instructions about when to stop and restart their blood thinners and taught how to self-administrator a short acting blood thinner (heparin) if needed. The COVID pandemic changed the way these appointments were done, making it important to contact these patients without them having to come to the hospital for an in person visit. Virtual patient care, by telephone or video conference, to communicate to patients about when to start and restart their blood thinner was necessary. This study wants to show that this virtual method of instruction, using a standardized plan of managing patient care, is easy, acceptable to patients and as safe when compared to an in-person meeting. Such instruction would also be cost-efficient standard post-pandemic. Prior work has shown that both a standard care of patients who are receiving blood thinners and a point-of-care decision "app", available through Thrombosis Canada (www.thrombosiscanada.ca) website, have been trusted during this virtual visit successfully. The investigator will show, by following up at 30 days, that this standardized management plan is safe and can be done virtually, with a low risk of stroke and major bleeding.

Recruiting

1 award

N/A

2 criteria